Rut­gers sci­en­tists form im­muno-on­col­o­gy biotech to de­vel­op pipeline of TAM in­hibitors

There are thou­sands of im­muno-on­col­o­gy ther­a­pies in the glob­al pipeline, and re­searchers from Rut­gers are adding to that tal­ly, with a fam­i­ly of com­pounds that could po­ten­tial­ly be used in tan­dem with es­tab­lished check­point in­hibitors for a pletho­ra of can­cers, as part of a new­ly formed biotech named Tam­Rx.

Fund­ed by Bio­Mo­tiv, the for-prof­it ac­cel­er­a­tor of The Har­ring­ton Project, Tam­Rx’s tech­nol­o­gy in­hibits TAM (Ty­ro3, Axl, and Mertk), a fam­i­ly of re­cep­tor ty­ro­sine ki­nas­es im­pli­cat­ed in a wide spec­trum of hu­man can­cers. El­e­vat­ed TAM sig­nal­ing is heav­i­ly as­so­ci­at­ed with can­cer pro­gres­sion, metas­ta­sis, and re­sis­tance to tar­get­ed ther­a­pies. Tam­Rx’s in­hibitors are de­signed to thwart tu­mor growth and metas­ta­sis and to stim­u­late the im­mune sys­tem to en­hance its an an­ti-tu­mor re­sponse, the com­pa­ny said on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER